The formation of a strategic partnership aims to further research in the treatment and prevention of equine disease.
Pfizer Animal Health and The Hippolia Foundation will form a strategic partnership to advance equine health through research and educational programmes.
The Hippolia Foundation – a network of leading French equine institutions together with international partners – will collaborate with Pfizer to accelerate advancement in innovation on the diagnosis, treatment and prevention of equine disease. The Hippolia partner organisations and Pfizer are initially investing more than $5 million over three years.
Pierre Lekeux, president of The Hippolia Foundation, said: “This is an excellent example of a public/private initiative to advance our scientific knowledge and improve animal health and welfare.”
The two principal areas of collaboration to be developed will focus on respiratory disorders and on infectious diseases.
“This is a particularly synergistic partnership,” said Alejandro Bernal, Area President, Pfizer Animal Health, Europe, Africa and Middle East.
“Both parties will benefit from the combined expertise and resources in the interests of accelerating pioneering equine research.”
In November 2011, Pfizer opened a new global Equine Research Center at its worldwide veterinary medicine research and development headquarters in greater Kalamazoo, Michigan.
Founded in 2011 and located in Normandy, The Hippolia Foundation supports and promotes the development of research programmes, training and services at an international level, particularly on issues of health, welfare and performance in horses.
The Normandy site has established a reputation as a world-class facility undertaking leading-edge research on racehorses (thoroughbred and standardbred) but also on sport horses.